Remus Pharmaceuticals was incorporated on September 21, 2015. The company is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. It also deals in API and provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries.
| Bidding Dates |
|---|
| 17 May 2023 - 19 May 2023 |
| Subscription |
|---|
| 57.21x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹1,22,900 | 1 | 1 | 100 | 388.0 K | ₹1150 - ₹1229 | 73.66 % | ₹446.2 M - ₹476.9 M | RHP DOC |
Remus Pharma IPO SUBSCRIPTION STATUS
19 May '23Remus Pharma IPO overall subscription rate was 57.21 times the total available shares
Remus Pharma IPO retail subscription rate was 49.81 times in the retail segment
Remus Pharma IPO non-institutional investor subscription rate was 229.31 times in the non-institutional investor category
Remus Pharma IPO Qualified Institutional Bidder subscription rate was 10.75 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
19 May 2023 (Day 3) | 49.81x | 229.31x | 10.75x |
18 May 2023 (Day 2) | 10.77x | 12.24x | 1.48x |
17 May 2023 (Day 1) | 2.78x | 2.83x | 0x |
Remus Pharma FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| 9MFY23 | 64.4 | 323.9 | 53.2 | 33.0 | 28.3% |
| FY22 | 33.9 | 247.2 | 50.4 | 49.7 | 19.4% |
| FY21 | 10.3 | 184.2 | 28.4 | 27.7 | 8.5% |
| FY20 | 8.1 | 119.2 | 13.0 | 7.4 | 10.4% |
Remus Pharma IPO SUBSCRIPTION STATUS DETAILS
Remus Pharma had 388.0 K shares on offer
Remus Pharma IPO offer price was in the range ₹1150 - ₹1229
Remus Pharma IPO minimum Investment was ₹122900
Remus Pharma IPO issue size was ₹ 446.2 M - ₹ 476.9 M
Remus Pharma had a minimum lot size of 100 Shares per application
Remus Pharma NUMBER OF SHARES ON OFFER
Remus Pharma IPO IMPORTANT DATES
| Issue Open Date | 17 May 2023 |
| Issue close Date | 19 May 2023 |
| Allotment Date | 24 May 2023 |
| Refund Date | 25 May 2023 |
| Demat Account Credit Date | 26 May 2023 |
| Listing Date | 29 May 2023 |
| Listing on Exchange(s) | NSE |
| Remus Pharma Allotment Status | Exchange |
Remus Pharma IPO subscription opened on 17 May 2023, and closed on 19 May 2023
IPO allotment for Remus Pharma was finalized on Wednesday, 24 May 2023
IPO listing for Remus Pharma was on NSE on Monday, 29 May 2023
Remus Pharma IPO LISTING GAINS
| Issue Price (adjusted) | 153.6 |
| Listing Open Price | 1711.3 |
| Listing Close Price | 1796.8 |
| Listing Gain% | 39.2% |
| Current Gain% | 448.2% |
Remus Pharma Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remus Pharmaceuticals Ltd. | 842.2 | 124.1 | 26.8 | -0.3 | 0.1 | 10.5 | 6.4 | 860.3 | 37.6 | 37 | 27.2 | 31.4 | -84.1 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Remus Pharma INFORMATION ON IPO ISSUE
About Remus Pharma
Remus Pharmaceuticals was incorporated on September 21, 2015. The company is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. It also deals in API and provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries.
Object of the Issue
- To meet working capital requirements
- Funding investments for acquisitions and general corporate purposes
- To meet public issue expenses
Remus Pharma - PROMOTERS
| Name |
|---|
| Arpit Deepakkumar Shah |
| Swapnil Jatinbhai Shah |
| Roma Vinodbhai Shah |
| Anar Swapnil Shah |
Remus Pharma Lead Manager to the Issue
Beeline Capital Advisors Private Limited
mb@beelinemb.com
Remus Pharma Registrar to the Issue
Link Intime India Private Limited
remuspharmaceuticals.ipo@linkintime.co.in
Remus Pharma Strengths
Wide range of products
The company's product portfolio consists of 429 products, as on January 31, 2023, and it operates under different brand names across the globe
Diversified business operations and revenue base
The business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry and it has marked its presence in international as well as Indian markets
Remus Pharma Risks
Outstanding legal proceedings
There are outstanding legal proceedings involving the company, the directors and the promoter
Dependent on few customers
The company is dependent on a few number of customers for sales. Loss of any of these large customer may affect the revenues and profitability
IPO FAQs
Remus Pharmaceuticals Ltd. IPO listing opened at Rs 1711.25 while the issue price was Rs 1229.00 giving 39.24% returns. After adjusting for subsequent bonus and splits, the stock trades at Rs 153.63 giving 448.23% gains since its IPO listing.
The promoters of the company are Arpit Deepakkumar Shah, Swapnil Jatinbhai Shah, Roma Vinodbhai Shah and Anar Swapnil Shah.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 1150.0 - 1229.0.
The IPO application opens on May 17, 2023 and closes on May 19, 2023.
The minimum lot size for the IPO is 100. The maximum lot size for the IPO is 100.
For all category investors, the minimum application amount for this IPO is Rs. 122,900.0, the maximum value for this IPO is Rs 122,900.0.
This IPO will be allotted on May 24, 2023.
The refund will be credited to your account on May 25, 2023.
The allotted shares will be credited to your demat on May 26, 2023.
Remus Pharmaceuticals Ltd.’s shares listed on the stock exchanges on May 29, 2023.